• ABPI Website
  • Media
  • ABPI response to meeting between industry and Government on HRT supply

ABPI response to meeting between industry and Government on HRT supply

The ABPI welcomed today’s meeting between industry and Government on HRT supply.

The shortage of some HRT products is a complex problem, and continued collaboration between Government, industry and the NHS is an important part of the solution. Richard Torbett, Chief Executive, ABPI

Chief Executive Richard Torbett said:

“Recent Government and media-led campaigns are incredibly important in helping women understand the benefits of HRT and get the medicines they need to support them.

“The shortage of some HRT products is a complex problem, and continued collaboration between Government, industry and the NHS is an important part of the solution.

“Intelligence sharing to determine demand is absolutely crucial, and will allow companies to take action to maintain supply wherever possible.

“Removing restrictions on prescribing of products in local areas could also prevent local variation in care and in prescribing practice, which in turn means medicines are less likely to run out of stock.

“Taken together, this should help smooth supply and demand, and help patients access treatments.”  

TAGS
  • Supply

Last modified: 20 September 2023

Last reviewed: 20 September 2023

The ABPI exists to make the UK the best place in the world to research, develop and use new medicines. We represent companies of all sizes who invest in discovering the medicines of the future. 

Our members supply cutting edge treatments that improve and save the lives of millions of people. We work in partnership with Government and the NHS so patients can get new treatments faster and the NHS can plan how much it spends on medicines. Every day, we partner with organisations in the life sciences community and beyond to transform lives across the UK.